Home > News > NIH Funds Clinical Development of VivaGel(TM)
April 19th, 2006
NIH Funds Clinical Development of VivaGel(TM)
Abstract:
Starpharma Holdings Limited (USOTC: SPHRY; ASX: SPL) today signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to fund a clinical trial to test the use of VivaGel(TM) in the prevention of genital herpes. Genital herpes is the second indication for which VivaGel(TM) is being developed. This latest support from the NIH is in addition to a previously announced US$20.3 (A$26m) million funding provided by the NIH to support the development of VivaGel(TM) for the prevention of HIV.
Source:
prnewswire
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||